Advertisement

Chronic myeloproliferative neoplasms in the elderly

  • Author Footnotes
    1 M.M. and E.O. contributed equally.
    Margherita Maffioli
    Footnotes
    1 M.M. and E.O. contributed equally.
    Affiliations
    Hematology, Department of Medicina Specialistica, ASST Sette Laghi, Ospedale di Circolo, Varese, Italy
    Search for articles by this author
  • Author Footnotes
    1 M.M. and E.O. contributed equally.
    Ester Orlandi
    Footnotes
    1 M.M. and E.O. contributed equally.
    Affiliations
    Hematology, I.R.C.C.S Fondazione Policlinico San Matteo, Pavia, Italy
    Search for articles by this author
  • Francesco Passamonti
    Correspondence
    Corresponding author at: Hematology, Dipartimento di Medicina e Chirurgia, University of Insubria, Via Guicciardini, 21100 Varese, Italy.
    Affiliations
    Hematology, Department of Medicina Specialistica, ASST Sette Laghi, Ospedale di Circolo, Varese, Italy

    Hematology, Department of Medicine and Surgery, University of Insubria, Varese, Italy
    Search for articles by this author
  • Author Footnotes
    1 M.M. and E.O. contributed equally.

      Abstract

      This review focuses on the management of elderly patients with chronic myeloid leukemia and chronic myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia and primary myelofibrosis. Median age in these neoplasms is within the 6th decades of age. All new therapies can be done at any age without absolute contraindication. However, the selection of the precise therapy for the single patient is mandatory. For these reasons, an accurate definition of diagnosis and prognostication is necessary. Precision in disease definition and prognostication is definitively helpful for personalizing therapeutic approach.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Jemal A.
        • Siegel R.
        • Xu J.
        • Ward E.
        Cancer statistics, 2010.
        CA Cancer J Clin. 2010; 60: 277-300
        • Hoffmann V.S.
        • Baccarani M.
        • Hasford J.
        • Lindoerfer D.
        • Burgstaller S.
        • Sertic D.
        • et al.
        The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European countries.
        Leukemia. 2015; 29: 1336-1343
        • Huang X.
        • Cortes J.
        • Kantarjian H.
        Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
        Cancer. 2012; 118: 3123-3127
        • Srour S.A.
        • Devesa S.S.
        • Morton L.M.
        • Check D.P.
        • Curtis R.E.
        • Linet M.S.
        • et al.
        Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12.
        Br J Haematol. 2016; 174: 382-396
        • Tefferi A.
        • Guglielmelli P.
        • Larson D.R.
        • Finke C.
        • Wassie E.A.
        • Pieri L.
        • et al.
        Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.
        Blood. 2014; 124 (quiz 615): 2507-2513
        • Arber D.A.
        • Orazi A.
        • Hasserjian R.
        • Thiele J.
        • Borowitz M.J.
        • Le Beau M.M.
        • et al.
        The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.
        Blood. 2016; 127: 2391-2405
        • Baccarani M.
        • Deininger M.W.
        • Rosti G.
        • Hochhaus A.
        • Soverini S.
        • Apperley J.F.
        • et al.
        European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
        Blood. 2013; 122: 872-884
        • Sokal J.E.
        • Cox E.B.
        • Baccarani M.
        • Tura S.
        • Gomez G.A.
        • Robertson J.E.
        • et al.
        Prognostic discrimination in "good-risk" chronic granulocytic leukemia.
        Blood. 1984; 63: 789-799
        • Hasford J.
        • Pfirrmann M.
        • Hehlmann R.
        • Allan N.C.
        • Baccarani M.
        • Kluin-Nelemans J.C.
        • et al.
        A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa writing Committee for the Collaborative CML prognostic factors project group.
        JNCI. 1998; 90: 850-859
        • Hasford J.
        • Baccarani M.
        • Hoffmann V.
        • Guilhot J.
        • Saussele S.
        • Rosti G.
        • et al.
        Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score.
        Blood. 2011; 118: 686-692
        • Cortes J.
        • Talpaz M.
        • O'Brien S.
        • Giles F.
        • Beth Rios M.
        • Shan J.
        • et al.
        Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
        Cancer. 2003; 98: 1105-1113
        • Hochhaus A.
        • O'Brien S.G.
        • Guilhot F.
        • Druker B.J.
        • Branford S.
        • Foroni L.
        • et al.
        Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.
        Leukemia. 2009; 23: 1054-1061
        • Latagliata R.
        • Breccia M.
        • Carmosino I.
        • Cannella L.
        • De Cuia R.
        • Diverio D.
        • et al.
        “Real-life” results of front-line treatment with Imatinib in older patients (≥65 years) with newly diagnosed chronic myelogenous leukemia.
        Leuk Res. 2010; 34: 1472-1475
        • Gugliotta G.
        • Castagnetti F.
        • Palandri F.
        • Breccia M.
        • Intermesoli T.
        • Capucci A.
        • et al.
        Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML working party.
        Blood. 2011; 117: 5591-5599
        • Rousselot P.
        • Cony-Makhoul P.
        • Nicolini F.
        • Mahon F.X.
        • Berthou C.
        • Réa D.
        • et al.
        Long-term safety and efficacy of imatinib mesylate (Gleevec®) in elderly patients with chronic phase chronic myelogenous leukemia: results of the AFR04 study.
        Am J Hematol. 2012; 88: 1-4
        • Castagnetti F.
        • Di Raimondo F.
        • De Vivo A.
        • Spitaleri A.
        • Gugliotta G.
        • Fabbiano F.
        • et al.
        A population-based study of chronic myeloid leukemia patients treated with imatinib in first line.
        Am J Hematol. 2016; 92: 82-87
        • Rohrbacher M.
        • Hasford J.
        Epidemiology of chronic myeloid leukaemia (CML).
        Best Pract Res Clin Haematol. 2009; 22: 295-302
        • Wiggins C.L.
        • Harlan L.C.
        • Nelson H.E.
        • Stevens J.L.
        • Willman C.L.
        • Libby E.N.
        • et al.
        Age disparity in the dissemination of imatinib for treating chronic myeloid leukemia.
        Am J Med. 2010; 123 (764.e1-.e9)
        • Björkholm M.
        • Ohm L.
        • Eloranta S.
        • Derolf Å.
        • Hultcrantz M.
        • Sjöberg J.
        • et al.
        Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008.
        J Clin Oncol. 2011; 29: 2514-2520
        • Hoglund M.
        • Sandin F.
        • Hellstrom K.
        • Bjoreman M.
        • Bjorkholm M.
        • Brune M.
        • et al.
        Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry.
        Blood. 2013; 122: 1284-1292
        • Saussele S.
        • Krauss M.P.
        • Hehlmann R.
        • Lauseker M.
        • Proetel U.
        • Kalmanti L.
        • et al.
        Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.
        Blood. 2015; 126: 42-49
        • Charlson M.E.
        • Pompei P.
        • Ales K.L.
        • MacKenzie C.R.
        A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
        J Chronic Dis. 1987; 40: 373-383
        • Latagliata R.
        • Ferrero D.
        • Iurlo A.
        • Cavazzini F.
        • Castagnetti F.
        • Abruzzese E.
        • et al.
        Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study.
        Drugs Aging. 2013; 30: 629-637
        • Breccia M.
        • Luciano L.
        • Latagliata R.
        • Castagnetti F.
        • Ferrero D.
        • Cavazzini F.
        • et al.
        Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival.
        Leuk Res. 2014; 38: 1173-1176
        • Cortes J.E.
        • Saglio G.
        • Kantarjian H.M.
        • Baccarani M.
        • Mayer J.
        • Boqué C.
        • et al.
        Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial.
        J Clin Oncol. 2016; 34: 2333-2340
        • Hochhaus A.
        • Saglio G.
        • Hughes T.P.
        • Larson R.A.
        • Kim D.W.
        • Issaragrisil S.
        • et al.
        Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.
        Leukemia. 2016; 30: 1044-1054
        • Brümmendorf T.H.
        • Cortes J.E.
        • de Souza C.A.
        • Guilhot F.
        • Duvillié L.
        • Pavlov D.
        • et al.
        Bosutinibversusimatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial.
        Br J Haematol. 2014; 168: 69-81
        • Larson R.A.
        • Bunworasate U.
        • Turkina A.G.
        • Goldberg S.L.
        • Dorlhiac-Llacer P.
        • Lopez J.L.
        • et al.
        Nilotinib shows safety and efficacy in older patients (≥65 years) with newly diagnosed chronic myeloid leukemia in chronic phase comparable with that in younger patients with chronic myeloid leukemia in chronic phase: results from ENESTnd.
        Blood. 2011; 118: 3768
        • Khoury H.J.
        • Cortes J.E.
        • Kantarjian H.
        • Baccarani M.
        • Shah N.P.
        • Bradley-Garelik M.B.
        • et al.
        Safety and efficacy of Dasatinib (DAS) vs. Imatinib (IM) by baseline comorbidity in patients with chronic myeloid leukemia in chronic phase (CML-CP): analysis of the DASISION trial.
        Blood. 2010; 116: 3421
        • Giles F.J.
        • Rea D.
        • Rosti G.
        • Cross N.C.P.
        • Steegmann J.L.
        • Griskevicius L.
        • et al.
        Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis.
        J Cancer Res Clin Oncol. 2017; 143: 1585-1596
        • Gugliotta G.
        • Castagnetti F.
        • Breccia M.
        • Levato L.
        • D'Adda M.
        • Stagno F.
        • et al.
        Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia.
        Haematologica. 2015; 100: 1146-1150
        • Castagnetti F.
        • Breccia M.
        • Gugliotta G.
        • Martino B.
        • Dadda M.
        • Stagno F.
        • et al.
        Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients.
        Haematologica. 2016; 101: 1200-1207
        • Breccia M.
        • Molica M.
        • Colafigli G.
        • Zacheo I.
        • Latagliata R.
        • Tafuri A.
        • et al.
        Correlation between Charlson comorbidity index and outcome in patients with chronic phase chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors upfront.
        Leuk Lymphoma. 2015; 56: 2206-2207
        • Latagliata R.
        • Stagno F.
        • Annunziata M.
        • Abruzzese E.
        • Iurlo A.
        • Guarini A.
        • et al.
        Frontline dasatinib treatment in a “real-life” cohort of patients older than 65 years with chronic myeloid leukemia.
        Neoplasia. 2016; 18: 536-540
        • Bower H.
        • Björkholm M.
        • Dickman P.W.
        • Höglund M.
        • Lambert P.C.
        • Andersson T.M.L.
        Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population.
        J Clin Oncol. 2016; 34: 2851-2857
        • Di Gion P.
        • Kanefendt F.
        • Lindauer A.
        • Scheffler M.
        • Doroshyenko O.
        • Fuhr U.
        • et al.
        Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.
        Clin Pharmacokinet. 2011; 50: 551-603
        • Cross N.C.P.
        • White H.E.
        • Müller M.C.
        • Saglio G.
        • Hochhaus A.
        Standardized definitions of molecular response in chronic myeloid leukemia.
        Leukemia. 2012; 26: 2172-2175
        • Pallera A.
        • Altman J.K.
        • Berman E.
        • Abboud C.N.
        • Bhatnagar B.
        • Curtin P.
        • et al.
        NCCN guidelines insights: chronic myeloid leukemia, version 1.2017.
        J Natl Compr Cancer Netw. 2016; 14: 1505-1512
        • Hochhaus A.
        • Saussele S.
        • Rosti G.
        • Mahon F.X.
        • Janssen J.J.W.M.
        • Hjorth-Hansen H.
        • et al.
        Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†.
        Ann Oncol. 2017; 28: iv41-iv51
        • Steegmann J.L.
        • Baccarani M.
        • Breccia M.
        • Casado L.F.
        • García-Gutiérrez V.
        • Hochhaus A.
        • et al.
        European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.
        Leukemia. 2016; 30: 1648-1671
        • Etienne G.
        • Guilhot J.
        • Rea D.
        • Rigal-Huguet F.
        • Nicolini F.
        • Charbonnier A.
        • et al.
        Long-term follow-up of the French stop Imatinib (STIM1) study in patients with chronic myeloid leukemia.
        J Clin Oncol. 2017; 35: 298-305
        • Hughes T.P.
        • Ross D.M.
        Moving treatment-free remission into mainstream clinical practice in CML.
        Blood. 2016; 128: 17-23
        • Jabbour E.
        • Makenbaeva D.
        • Lingohr-Smith M.
        • Lin J.
        Use of real-world claim databases to assess prevalence of comorbid conditions relevant to the treatment of chronic myelogenous leukemia based on National Comprehensive Network Treatment Guidelines.
        Clin Lymphoma Myeloma Leukemia. 2015; 15: 797-802.e1
        • Russo D.
        • Martinelli G.
        • Malagola M.
        • Skert C.
        • Soverini S.
        • Iacobucci I.
        • et al.
        Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia.
        Blood. 2013; 121: 5138-5144
        • Mori S.
        • Vagge E.
        • le Coutre P.
        • Abruzzese E.
        • Martino B.
        • Pungolino E.
        • et al.
        Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study.
        Am J Hematol. 2015; 90: 910-914
        • Kantarjian H.M.
        • Giles F.J.
        • Bhalla K.N.
        • Pinilla-Ibarz J.
        • Larson R.A.
        • Gattermann N.
        • et al.
        Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.
        Blood. 2011; 117: 1141-1145
        • Shah N.P.
        • Rousselot P.
        • Schiffer C.
        • Rea D.
        • Cortes J.E.
        • Milone J.
        • et al.
        Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.
        Am J Hematol. 2016; 91: 869-874
        • Gambacorti-Passerini C.
        • Brümmendorf T.H.
        • Kim D.-W.
        • Turkina A.G.
        • Masszi T.
        • Assouline S.
        • et al.
        Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: minimum 24-month follow-up.
        Am J Hematol. 2014; 89: 732-742
        • Cortes J.E.
        • Kim D.W.
        • Pinilla-Ibarz J.
        • le Coutre P.
        • Paquette R.
        • Chuah C.
        • et al.
        A phase 2 trial of Ponatinib in Philadelphia chromosome–positive Leukemias.
        N Engl J Med. 2013; 369: 1783-1796
        • Cortes J.E.
        • Jean Khoury H.
        • Kantarjian H.
        • Brümmendorf T.H.
        • Mauro M.J.
        • Matczak E.
        • et al.
        Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib.
        Am J Hematol. 2016; 91: 606-616
        • Soverini S.
        • Hochhaus A.
        • Nicolini F.E.
        • Gruber F.
        • Lange T.
        • Saglio G.
        • et al.
        BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.
        Blood. 2011; 118: 1208-1215
        • Passamonti F.
        How I treat polycythemia vera.
        Blood. 2012; 120: 275-284
        • Passamonti F.
        • Brusamolino E.
        • Lazzarino M.
        • Barate C.
        • Klersy C.
        • Orlandi E.
        • et al.
        Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients.
        Haematologica. 2000; 85: 1011-1018
        • Cervantes F.
        • Dupriez B.
        • Pereira A.
        • Passamonti F.
        • Reilly J.T.
        • Morra E.
        • et al.
        New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.
        Blood. 2009; 113: 2895-2901
        • Vardiman J.W.
        • Thiele J.
        • Arber D.A.
        • Brunning R.D.
        • Borowitz M.J.
        • Porwit A.
        • et al.
        The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.
        Blood. 2009; 114: 937-951
        • Barosi G.
        • Mesa R.A.
        • Thiele J.
        • Cervantes F.
        • Campbell P.J.
        • Verstovsek S.
        • et al.
        Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment.
        Leukemia. 2008; 22 (England): 437-438
        • Passamonti F.
        • Rumi E.
        • Pietra D.
        • Elena C.
        • Boveri E.
        • Arcaini L.
        • et al.
        A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications.
        Leukemia. 2010; 24: 1574-1579
        • Passamonti F.
        • Mora B.
        • Maffioli M.
        New molecular genetics in the diagnosis and treatment of myeloproliferative neoplasms.
        Curr Opin Hematol. 2016; 23: 137-143
        • Milosevic Feenstra J.D.
        • Nivarthi H.
        • Gisslinger H.
        • Leroy E.
        • Rumi E.
        • Chachoua I.
        • et al.
        Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms.
        Blood. 2016; 127: 325-332
        • Olcaydu D.
        • Rumi E.
        • Harutyunyan A.
        • Passamonti F.
        • Pietra D.
        • Pascutto C.
        • et al.
        The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms.
        Haematologica. 2011; 96: 367-374
        • Passamonti F.
        • Elena C.
        • Schnittger S.
        • Skoda R.C.
        • Green A.R.
        • Girodon F.
        • et al.
        Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations.
        Blood. 2011; 117: 2813-2816
        • Passamonti F.
        • Maffioli M.
        Update from the latest WHO classification of MPNs: a user's manual.
        Hematology Am Soc Hematol Educ Program. 2016; 2016: 534-542
        • Tefferi A.
        • Lasho T.L.
        • Finke C.
        • Belachew A.A.
        • Wassie E.A.
        • Ketterling R.P.
        • et al.
        Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact.
        Leukemia. 2014; 28 (England): 1568-1570
        • Tefferi A.
        • Wassie E.A.
        • Guglielmelli P.
        • Gangat N.
        • Belachew A.A.
        • Lasho T.L.
        • et al.
        Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients.
        Am J Hematol. 2014; 89: E121-E124
        • Barbui T.
        • Barosi G.
        • Birgegard G.
        • Cervantes F.
        • Finazzi G.
        • Griesshammer M.
        • et al.
        Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.
        J Clin Oncol. 2011; 29: 761-770
        • Marchioli R.
        • Finazzi G.
        • Landolfi R.
        • Kutti J.
        • Gisslinger H.
        • Patrono C.
        • et al.
        Vascular and neoplastic risk in a large cohort of patients with polycythemia vera.
        J Clin Oncol. 2005; 23: 2224-2232
        • Carobbio A.
        • Finazzi G.
        • Antonioli E.
        • Guglielmelli P.
        • Vannucchi A.M.
        • Delaini F.
        • et al.
        Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia.
        Blood. 2008; 112: 3135-3137
        • Barbui T.
        • Finazzi G.
        • Carobbio A.
        • Thiele J.
        • Passamonti F.
        • Rumi E.
        • et al.
        Development and validation of an international prognostic score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis).
        Blood. 2012; 120 (quiz 252): 5128-5133
        • Barbui T.
        • Vannucchi A.M.
        • Carobbio A.
        • Rumi E.
        • Finazzi G.
        • Gisslinger H.
        • et al.
        The effect of arterial hypertension on thrombosis in low-risk polycythemia vera.
        Am J Hematol. 2017; 92: E5-E6
      1. Barbui T, Carobbio A, Rambaldi A, Finazzi G. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood. 1142009. p. 759–63.

        • Jose S.S.
        • Bendickova K.
        • Kepak T.
        • Krenova Z.
        • Fric J.
        Chronic inflammation in immune aging: role of pattern recognition receptor crosstalk with the telomere complex?.
        Front Immunol. 2017; 8: 1078
        • Barraco D.
        • Cerquozzi S.
        • Hanson C.A.
        • Ketterling R.P.
        • Pardanani A.
        • Gangat N.
        • et al.
        Prognostic impact of bone marrow fibrosis in polycythemia vera: validation of the IWG-MRT study and additional observations.
        Blood Cancer J. 2017; (72017): e538
        • Passamonti F.
        • Thiele J.
        • Girodon F.
        • Rumi E.
        • Carobbio A.
        • Gisslinger H.
        • et al.
        A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment.
        Blood. 2012; 120: 1197-1201
        • Tefferi A.
        • Rumi E.
        • Finazzi G.
        • Gisslinger H.
        • Vannucchi A.M.
        • Rodeghiero F.
        • et al.
        Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study.
        Leukemia. 2013; 27: 1874-1881
        • Cervantes F.
        • Dupriez B.
        • Passamonti F.
        • Vannucchi A.M.
        • Morra E.
        • Reilly J.T.
        • et al.
        Improving survival trends in primary myelofibrosis: an international study.
        J Clin Oncol. 2012; 30: 2981-2987
        • Passamonti F.
        • Cervantes F.
        • Vannucchi A.M.
        • Morra E.
        • Rumi E.
        • Pereira A.
        • et al.
        A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).
        Blood. 2010; 115: 1703-1708
        • Passamonti F.
        • Cervantes F.
        • Vannucchi A.M.
        • Morra E.
        • Rumi E.
        • Cazzola M.
        • et al.
        Dynamic international prognostic scoring system (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis.
        Blood. 2010; 116 (United States): 2857-2858
        • Gangat N.
        • Caramazza D.
        • Vaidya R.
        • George G.
        • Begna K.
        • Schwager S.
        • et al.
        DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.
        J Clin Oncol. 2011; 29: 392-397
        • Tefferi A.
        • Lasho T.L.
        • Finke C.M.
        • Knudson R.A.
        • Ketterling R.
        • Hanson C.H.
        • et al.
        CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons.
        Leukemia. 2014; 28: 1472-1477
        • Rumi E.
        • Pietra D.
        • Pascutto C.
        • Guglielmelli P.
        • Martinez-Trillos A.
        • Casetti I.
        • et al.
        Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.
        Blood. 2014; 124: 1062-1069
        • Tefferi A.
        • Guglielmelli P.
        • Lasho T.L.
        • Rotunno G.
        • Finke C.
        • Mannarelli C.
        • et al.
        CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients.
        Leukemia. 2014; 28: 1494-1500
        • Vannucchi A.M.
        • Lasho T.L.
        • Guglielmelli P.
        • Biamonte F.
        • Pardanani A.
        • Pereira A.
        • et al.
        Mutations and prognosis in primary myelofibrosis.
        Leukemia. 2013; 27: 1861-1869
        • Guglielmelli P.
        • Lasho T.L.
        • Rotunno G.
        • Score J.
        • Mannarelli C.
        • Pancrazzi A.
        • et al.
        The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients.
        Leukemia. 2014; 28: 1804-1810
        • Tefferi A.
        • Jimma T.
        • Gangat N.
        • Vaidya R.
        • Begna K.H.
        • Hanson C.A.
        • et al.
        Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients.
        Blood. 2011; 118: 4595-4598
        • Passamonti F.
        • Giorgino T.
        • Mora B.
        • Guglielmelli P.
        • Rumi E.
        • Maffioli M.
        • et al.
        A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.
        Leukemia. 2017; 31: 2726-2731
        • Rotunno G.
        • Pacilli A.
        • Artusi V.
        • Rumi E.
        • Maffioli M.
        • Delaini F.
        • et al.
        Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: a study on 359 patients of the AGIMM group.
        Am J Hematol. 2016; 91: 681-686
        • Marchioli R.
        • Finazzi G.
        • Specchia G.
        • Cacciola R.
        • Cavazzina R.
        • Cilloni D.
        • et al.
        Cardiovascular events and intensity of treatment in polycythemia vera.
        N Engl J Med. 2013; 368: 22-33
        • Bjorkholm M.
        • Derolf A.R.
        • Hultcrantz M.
        • Kristinsson S.Y.
        • Ekstrand C.
        • Goldin L.R.
        • et al.
        Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms.
        J Clin Oncol. 2011; 29: 2410-2415
        • Gangat N.
        • Strand J.
        • Li C.Y.
        • Wu W.
        • Pardanani A.
        • Tefferi A.
        Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation.
        Br J Haematol. 2007; 138: 354-358
        • Masarova L.
        • Patel K.P.
        • Newberry K.J.
        • Cortes J.
        • Borthakur G.
        • Konopleva M.
        • et al.
        Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial.
        Lancet Haematol. 2017; 4e165-e75
        • Barosi G.
        • Birgegard G.
        • Finazzi G.
        • Griesshammer M.
        • Harrison C.
        • Hasselbalch H.
        • et al.
        A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process.
        Br J Haematol. 2010; 148: 961-963
        • Alvarez-Larran A.
        • Kerguelen A.
        • Hernandez-Boluda J.C.
        • Perez-Encinas M.
        • Ferrer-Marin F.
        • Barez A.
        • et al.
        Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera.
        Br J Haematol. 2016; 172: 786-793
        • Brusamolino E.
        • Lunghi F.
        • Orlandi E.
        • Astori C.
        • Passamonti F.
        • Barate C.
        • et al.
        Treatment of early-stage Hodgkin's disease with four cycles of ABVD followed by adjuvant radio-therapy: analysis of efficacy and long-term toxicity.
        Haematologica. 2000; 85: 1032-1039
        • Passamonti F.
        • Griesshammer M.
        • Palandri F.
        • Egyed M.
        • Benevolo G.
        • Devos T.
        • et al.
        Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study.
        Lancet Oncol. 2017; 18: 88-99
        • Vannucchi A.M.
        • Kiladjian J.J.
        • Griesshammer M.
        • Masszi T.
        • Durrant S.
        • Passamonti F.
        • et al.
        Ruxolitinib versus standard therapy for the treatment of polycythemia vera.
        N Engl J Med. 2015; 372: 426-435
        • Cervantes F.
        • Alvarez-Larran A.
        • Hernandez-Boluda J.C.
        • Sureda A.
        • Torrebadell M.
        • Montserrat E.
        Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature.
        Br J Haematol. 2004; 127: 399-403
        • Cervantes F.
        • Alvarez-Larran A.
        • Hernandez-Boluda J.C.
        • Sureda A.
        • Granell M.
        • Vallansot R.
        • et al.
        Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia.
        Br J Haematol. 2006; 134: 184-186
        • Cervantes F.
        • Alvarez-Larran A.
        • Domingo A.
        • Arellano-Rodrigo E.
        • Montserrat E.
        Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients.
        Br J Haematol. 2005; 129: 771-775
        • Mesa R.A.
        • Steensma D.P.
        • Pardanani A.
        • Li C.Y.
        • Elliott M.
        • Kaufmann S.H.
        • et al.
        A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia.
        Blood. 2003; 101: 2534-2541
        • Mesa R.A.
        • Yao X.
        • Cripe L.D.
        • Li C.Y.
        • Litzow M.
        • Paietta E.
        • et al.
        Lenalidomide and prednisone for myelofibrosis: eastern cooperative oncology group (ECOG) phase 2 trial E4903.
        Blood. 2010; 116: 4436-4438
        • Tefferi A.
        • Al-Ali H.K.
        • Barosi G.
        • Devos T.
        • Gisslinger H.
        • Jiang Q.
        • et al.
        A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.
        Leukemia. 2017; 31: 896-902
        • Tefferi A.
        • Verstovsek S.
        • Barosi G.
        • Passamonti F.
        • Roboz G.J.
        • Gisslinger H.
        • et al.
        Pomalidomide is active in the treatment of anemia associated with myelofibrosis.
        J Clin Oncol. 2009; 27: 4563-4569
        • Bose P.
        • Daver N.
        • Jabbour E.J.
        • Pike A.
        • Newberry K.J.
        Zhou L, et al.
        in: Phase-2 study of sotatercept (ACE-011) in myeloproliferative neoplasm-associated myelofibrosis and anemia. 2016
        • Verstovsek S.
        • Mesa R.A.
        • Gotlib J.
        • Levy R.S.
        • Gupta V.
        • DiPersio J.F.
        • et al.
        A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
        N Engl J Med. 2012; 366: 799-807
        • Harrison C.
        • Kiladjian J.J.
        • Al-Ali H.K.
        • Gisslinger H.
        • Waltzman R.
        • Stalbovskaya V.
        • et al.
        JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
        N Engl J Med. 2012; 366: 787-798
        • Verstovsek S.
        • Mesa R.A.
        • Gotlib J.
        • Levy R.S.
        • Gupta V.
        • DiPersio J.F.
        • et al.
        The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, phase III study in patients with myelofibrosis.
        Br J Haematol. 2013; 161: 508-516
        • Polverelli N.
        • Breccia M.
        • Benevolo G.
        • Martino B.
        • Tieghi A.
        • Latagliata R.
        • et al.
        Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients.
        Am J Hematol. 2017; 92: 37-41
        • Passamonti F.
        • Maffioli M.
        • Cervantes F.
        • Vannucchi A.M.
        • Morra E.
        • Barbui T.
        • et al.
        Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts.
        Blood. 2014; 123: 1833-1835
        • Al-Ali H.K.
        • Griesshammer M.
        • le Coutre P.
        • Waller C.F.
        • Liberati A.M.
        • Schafhausen P.
        • et al.
        Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial.
        Haematologica. 2016; 101: 1065-1073
      2. Raanani P. Gupta V. Sadjadian P. Al-Ali H.K. Giraldo P. Guglielmelli P. Safety and efficacy of ruxolitinib (Rux) in elderly patients (≥75 years) with myelofibrosis (Mf): An analysis from the phase 3b, expanded-access jump study. 2017